• Relay Medical (RELA) has appointed Bernard O’Brien, Keith Davis, and Donal Smith to its Strategic Advisory Board
  • The new board members have experience in the cruise ship industry and with the Caribbean government
  • Relay plans to leverage that experience to market its Fionet rapid testing platform in the CARICOM Region
  • Relay Medical is focused on novel technologies in the diagnostics and AI data science sectors
  • Relay Medical (RELA) is down 4.92 per cent and is currently trading at C$0.58 per share

Relay Medical (RELA) has appointed Bernard O’Brien, Keith Davis, and Donal Smith to its Strategic Advisory Board.

The new board members will assist the company to reach out to potential markets for the Fionet Testing Platform in the CARICOM Region.

CARICOM (Caribbean Community and Common Market) is an organization of 15 states, five associate members and other participants throughout the Caribbean. The organization’s objective to promote economic integration and cooperation among its members.

The Fionet platform is a rapid testing platform that Relay developed. It has been used to test individuals for COVID-19 and its variants.

Bernard O’Brien is an Information Systems Fleet Manager with Carnival Cruise Line.

The introduction of the Fionet platform on cruise ships would mean that ships may be able to start sailing again. Cruise ships have been on a no sail order since the start of the pandemic.

The platform would ensure that passengers and crew are tested and pronounced negative before boarding the ship.

“The industry needs a solution to begin cruising again. Data is key when it comes to tackling COVID-19 and Relay Medical’s Fionet is an obvious choice to provide that intelligence,” said Mr. O’Brien.

To complement Mr. O’Brien’s technical expertise, Relay is appointing two advisors familiar with the Caribbean Government to the Strategic Advisory Board.

Keith Davis and Donal Smith have served a combined almost 40 years in government. They will leverage that experience to assist Relay with implementing the Fionet platform in the CARICOM Region.

The platform would be used to manage COVID-19 and its variants in communities, businesses, and public health sectors throughout the region.

“We are very enthusiastic to be associated with the Fionet mobile Rapid Diagnostic Testing & Tracking platform regarding COVID-19, and other infectious disease response and management,” said Mr. Davis.

Mr. Smith added, “Introducing this cutting-edge technology will assist the region in returning to much needed social and economic sustainability.”

Relay Medical is focused on novel technologies in the diagnostics and AI data science sectors.

Relay Medical (RELA) is down 4.92 per cent and is currently trading at C$0.58 per share, as of 2:46 pm ET.

More From The Market Online

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.